Table 1.
Summary of ROS1 Cases
| Case | Sex | Age, years | Treatment | PFS During Pemetrexed Treatment (mo) |
|---|---|---|---|---|
| 1 | F | 35 | CPB × 6 → PB × 21 → P × >14a | >36 |
| 2 b | M | 64 | CPB × 6 → PB × 37 → P × >19c | >47 |
| 3 | F | 56 | CP × 4 → P × 18 → crizotinib | 18 |
| 4 d | F | 65 | C-Pac × 4 → P × 24 | 24 |
Abbreviations: B = bevacizumab; C = carboplatin; F = female; M = male; P = pemetrexed; Pac = paclitaxel; PFS = progression-free survival.
a
Bevacizumab discontinued because of nonspecific neurologic complaints.
b
Case 2 initially stage IIIB at diagnosis and received concurrent chemoradiation with biopsy proven recurrence 1 year later.
c
Bevacizumab discontinued because of proteinuria.
d
Case 4 is the only patient who received pemetrexed as second-line treatment. She died from treatment-related complications, not progression.